Herantis Pharma develops HER-096, a CDNF‑derived peptidomimetic that modulates the unfolded protein response to address proteostasis, mitochondrial dysfunction, and neuroinflammation in Parkinson’s disease. The subcutaneously administered molecule has shown favorable safety, brain penetration, and biomarker activity in Phase 1 trials and is being prepared for a randomized Phase 2 proof‑of‑concept study. The company seeks partnership opportunities to co‑develop or license this disease‑modifying therapy.
Funding
$5.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson’s disease currently lacks therapies that can modify its underlying progression, leaving patients dependent on symptomatic treatments that do not halt neurodegeneration. This creates an unmet medical need for interventions that address the disease’s core mechanisms such as proteostasis imbalance, mitochondrial dysfunction, and neuroinflammation.
Solution
Herantis Pharma is developing HER-096, a CDNF‑derived peptidomimetic designed to modulate the unfolded protein response and target multiple pathogenic pathways in Parkinson’s disease. The molecule is administered subcutaneously, has demonstrated favorable safety, efficient brain penetration, and biomarker evidence of biological activity in Phase 1 trials. Herantis plans to advance HER-096 into a randomized, signal‑seeking Phase 2 proof‑of‑concept study in early‑stage patients, aiming to provide the first disease‑modifying treatment for Parkinson’s. The company pursues a partnership‑driven strategy to support late‑stage development and eventual commercialization.
Target Audience
Primary customers are pharmaceutical partners and biotech companies seeking to co‑develop or license a disease‑modifying therapy for Parkinson’s disease, as well as clinical research organizations conducting early‑stage neurodegenerative trials.
Features
- CDNF‑derived peptidomimetic that engages the unfolded protein response to restore proteostasis
- Multi‑target activity addressing mitochondrial dysfunction and neuroinflammation
- Subcutaneous delivery with demonstrated ability to cross the blood‑brain barrier
- Phase 1 data showing a favorable safety profile and translational biomarker signals of target engagement
- Planned randomized Phase 2 proof‑of‑concept trial in early Parkinson’s disease patients